Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$82.44 USD

82.44
4,223,558

+1.40 (1.73%)

Updated Aug 23, 2024 04:00 PM ET

Pre-Market: $82.17 -0.27 (-0.33%) 8:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for MRNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Moderna, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 8,604 9,902 10,727 4,609 1,104
Receivables 892 1,385 3,175 1,391 5
Notes Receivable 0 0 0 0 0
Inventories 202 949 1,441 47 0
Other Current Assets 627 1,195 728 252 19
Total Current Assets 10,325 13,431 16,071 6,298 1,129
Net Property & Equipment 1,945 2,018 1,241 297 202
Investments & Advances 4,677 8,318 6,843 639 160
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 81 982 326 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 685 988 46 13 13
Total Assets 18,426 25,858 24,669 7,337 1,589
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 520 487 302 18 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 1,798 2,101 1,472 470 68
Income Taxes Payable 63 48 876 0 0
Other Current Liabilities 634 2,287 6,478 3,901 68
Total Current Liabilities 3,015 4,923 9,128 4,389 143
Mortgages 0 0 0 0 0
Deferred Taxes/Income 83 673 615 177 139
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 575 912 599 110 39
Other Non-Current Liabilities 256 135 76 2 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 4,572 6,735 10,524 4,775 415
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 371 1,173 4,211 4,802 2,669
Retained Earnings 13,606 18,320 9,958 -2,244 -1,496
Other Equity -123 -370 -24 3 2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 13,854 19,123 14,145 2,561 1,175
Total Liabilities & Shareholder's Equity 18,426 25,858 24,669 7,337 1,589
Total Common Equity 13,854 19,123 14,145 2,561 1,175
Shares Outstanding 381.20 384.10 405.40 395.70 336.50
Book Value Per Share 36.34 49.79 34.89 6.47 3.49

Fiscal Year End for Moderna, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 8,488 8,523 8,604 7,573 8,459
Receivables 163 137 892 1,866 232
Notes Receivable 0 0 0 0 0
Inventories 399 295 202 487 715
Other Current Assets 611 645 627 873 1,193
Total Current Assets 9,661 9,600 10,325 10,799 10,599
Net Property & Equipment 2,196 2,063 1,945 1,952 2,280
Investments & Advances 2,326 3,638 4,677 5,273 6,105
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 81 81 81 0 1,480
Intangibles 0 0 0 0 0
Deposits & Other Assets 641 650 685 661 1,290
Total Assets 15,680 16,729 18,426 19,450 21,884
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 279 183 520 494 310
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 1,333 1,396 1,798 2,224 1,490
Income Taxes Payable 7 52 63 56 47
Other Current Liabilities 744 749 634 1,611 1,276
Total Current Liabilities 2,363 2,380 3,015 4,385 3,123
Mortgages 0 0 0 0 0
Deferred Taxes/Income 95 58 83 166 692
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 576 575 575 575 843
Other Non-Current Liabilities 266 256 172 173
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,968 3,912 4,572 5,995 4,935
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 631 487 371 277 193
Retained Earnings 11,152 12,431 13,606 13,389 17,019
Other Equity -71 -101 -123 -211 -263
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 11,712 12,817 13,854 13,455 16,949
Total Liabilities & Shareholder's Equity 15,680 16,729 18,426 19,450 21,884
Total Common Equity 11,712 12,817 13,854 13,455 16,949
Shares Outstanding 384.40 383.20 381.20 381.20 381.20
Book Value Per Share 30.47 33.45 36.34 35.30 44.46